The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Finite therapies with the combination of BTKis and venetoclax in CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses finite therapy using a BTK inhibitor (BTKi) plus venetoclax for chronic lymphocytic leukemia (CLL). The combination of ibrutinib and venetoclax is now approved in Europe, easy to administer, and effective even for high-risk patients. At a follow-up of 5.5 years, there is a 70% response rate in patients with unmutated immunoglobulins and a 50% response rate in those with TP53 mutations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Consultancy: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Honoraria: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche.
